Aequus To Begin Proof of Concept Clinical Trial of Anti-Nausea Patch

Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) obtained approval from Health Canada to begin a clinical trial to evaluate the bioavailability and safety of the company’s transdermal anti-nausea patch, AQS1303.
As quoted in the press release:

AQS1303 is designed to provide patients with a more convenient and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times per day.
As previously announced, this first Proof of Concept study will be a single-dose cross-over comparative bioavailability study versus the currently approved oral version, Diclegis^®/Diclectin^®, in nine healthy volunteers. Results from this study are expected to be released by the end of this current quarter.
“Diclegis^®/Diclectin^® has provided symptomatic relief to millions of women to date, but in its current form it is dosed orally multiple times per day which can induce gag reflexes in women experiencing nausea during pregnancy,” said Anne Stevens, Chief Operating Officer and Director at Aequus. “We are very excited about the potential for this program and believe a long-acting patch could provide a much needed solution for this medication, giving patients a more comfortable and convenient dosing alternative.”

Click here to read the full press release.

Source: www.marketwired.com